Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

The firm saw an improvement in progression-free survival for patients on the ivonescimab regimen and a trend toward improved overall survival.

AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody ...

Nearly thirty years ago an academic paper wrongly linked autism to a measles vaccine. The impacts are still being felt today.

This is an ASCO Meeting Abstract from the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium. This abstract does not include a full text component.

References [1]  Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol 2021; 9: 373–92. [2]  Institute ...

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

This story contains details from testimony referencing suicide and suicidal ideations that are graphic, and some readers may ...

The FDA should now consider setting minimum thresholds for diverse inclusion, particularly in later-phase clinical trials. The FDA could also grant companies contingent approval (for example ...

Innovent announces phase 3 study of mazdutide in Chinese adults with overweight or obesity (GLORY-1) published in the NEJM: San Francisco, US Tuesday, May 27, 2025, 11:00 Hrs [IST ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...